Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

FDA accepts IND application to initiate human clinical trial to evaluate BNC

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) to begin human clinical trials and evaluate the safety and efficacy of the company's second product, bisnorcymserine (BNC).

3 Dec 2010

Soy bean derived compound could treat Sanfilippo genetic disease in children

Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.

2 Dec 2010

Dec. 1 news from RSNA 2010

The risk of developing radiation-induced cancer from computed tomography (CT) may be lower than previously thought, according to a Stanford University study. Using more than 10 million Medicare claims from 1998 through 2005, the researchers analyzed the distribution of CT scans, determined the ionizing radiation exposure associated with the exams and estimated the associated cancer risk in a population of older adults.

1 Dec 2010

New experimental device could offer effective treatment option for people with swallowing disorders

In what might be one of the world's first medicinal body piercings, UC Davis Health System surgeons announced today that they have successfully implanted an experimental device in the throat of a man that will enable him to manually control his ability to swallow.

1 Dec 2010

Diabetes plays a vital role in regulating brain cholesterol: Research

The brain contains more cholesterol than any other organ in the body, has to produce its own cholesterol and won't function normally if it doesn't churn out enough. Defects in cholesterol metabolism have been linked with Alzheimer's disease and other neurodegenerative conditions. Now researchers at Joslin Diabetes Center have discovered that diabetes can affect how much cholesterol the brain can make.

1 Dec 2010

Mitochondrial brain changes contribute to risk of Alzheimer's disease: Research

What are the earliest brain changes associated with the risk of developing Alzheimer's disease. A scientific report published in the October Journal of Alzheimer's Disease finds reduced activity of an energy-generating enzyme in deceased young adult brain donors who carry a common genetic risk factor for Alzheimer's disease.

1 Dec 2010

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

KineMed Inc. presents data on the new use of cerebrospinal fluid biomarkers of microtubule-mediated neuronal transport for the monitoring of disease progression and the advancement of therapeutic interventions in Parkinson's disease, a debilitating neurological condition with considerable unmet need for new treatments.

1 Dec 2010

Research could lead to new drug treatment for metabolic diseases

A team of Harvard School of Public Health (HSPH) scientists report finding a molecular "switch" that can "turn off" some cellular processes that are protective against aging and metabolic diseases. While more research is needed, the findings may open doors for new drug treatments to halt or slow development of metabolic diseases like type 2 diabetes or heart disease. The research findings appear in the December 1, 2010 issue of Cell Metabolism.

1 Dec 2010

MRS imaging technique may help diagnose chronic traumatic encephalopathy

In a study of ex-pro athletes, researchers found that a specialized imaging technique called magnetic resonance spectroscopy (MRS) may help diagnose chronic traumatic encephalopathy (CTE), a disorder caused by repetitive head trauma that currently can only be definitively diagnosed at autopsy. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2010

New tool helps gauge care for people with neurological disorder

A national conversation continues about the best ways to improve both the quality of medical care and to contain costs. So far, developing quality measurements has focused on primary care or highly prevalent, chronic conditions such as asthma and diabetes. But what about brain disorders? To date, the number of measures that apply to neurologic care has been limited.

1 Dec 2010

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Aphios® Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute of Aging (NIA), National Institutes of Health (NIH) for Developing a Novel Alzheimer's Disease Nanodrug.

30 Nov 2010

Neuraltus reports positive results from NP001 Phase 1 study for ALS

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1 clinical study of NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Nov 2010

New tool helps doctors gauge how well they care for people with Parkinson's disease

The American Academy of Neurology has developed a new tool to help doctors gauge how well they are caring for people with Parkinson's disease. The new quality measures are published in the November 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

30 Nov 2010

Molecular switch plays crucial role in addictive behavior and memory processes

Learning and memory formation are based on the creation of new connections between neurons in the brain. Also, behaviors such as nicotine addiction manifest themselves in long-term changes of neuronal connectivity and can - at least in this respect - be viewed as a form of learning.

30 Nov 2010

Resverlogix files new patent for dosing combinations of RVX-208, statin therapeutics

Resverlogix Corp. is pleased to announce today that it has filed additional new patent protection based on novel findings derived from its recently completed ASSERT Phase 2 clinical trial.

30 Nov 2010

Nine out of ten of all primary care centers in Sweden prescribe physical activity

Prescribing physical activity for the purpose of preventing and treating various conditions can now become a reality for healthcare professionals all over the world.

30 Nov 2010

biOasis commences research agreement with NRC

biOasis Technologies Inc. announced today that it has commenced a sponsored research agreement with the National Research Council of Canada. Under the terms of the agreement, the NRC will evaluate the ability of biOasis' compounds to cross the blood-brain barrier using time-domain in vivo optical imaging.

30 Nov 2010

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.

30 Nov 2010

Ageing reversed in mice: Study

A scientific team at Harvard-affiliated medical centers genetically manipulated mice to age faster. Then they used gene therapy to lengthen telomeres. Telomeres are compounds found at the ends of strands of DNA that are related to age. This lengthening of telomeres reversed age-related problems such as decreased brain function and infertility.

29 Nov 2010

Common, overprescribed drugs lead to election dopiness and immaturity

As Bill Maher, New York Magazine, the Washington Post and countless cable news and Internet sources have pointed out, the 2010 midterm campaigns and elections seem to have brought to light an American electorate capable of shocking illogic, ignorance and even violence.

29 Nov 2010